Vibha is a senior writer covering pharmaceutical and medtech regulatory developments across the globe. She plays a key role in tracking and writing about news of important regulatory issues affecting the sectors, and explaining their implications for industry. Vibha's fields of interest include the EU regulations on clinical trials, pharmacovigilance and pediatrics, on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Latest from Vibha Sharma

Kygevvi And Kayshild Among Six Products To Get EMA Nod As Tavneos Faces Data Integrity Scrutiny

The EMA has voted in favor of EU approval for five new products, including treatments for a rare, life‑threatening genetic disorder and for non‑cirrhotic MASH, and has also recommended reversing its earlier rejection of an orphan drug for chronic graft‑versus‑host disease.

Predictable Yet Flexible: Sponsor-Driven Timelines Underpin UK’s New Clinical Trials Regime

The UK MHRA says it is ready to deliver the new Clinical Trials Regulation, which aims to balance faster review of trial applications with greater flexibility to deliver a competitive, innovation-friendly clinical research ecosystem.

Semaglutide For MASH Among Five New Products Awaiting EMA Verdict

The European Medicines Agency is set to adopt opinions on whether marketing approval should be granted to five new products, including therapies for a serious liver disease and an ultra‑rare genetic mitochondrial disorder.

Faster Or Forgotten? Europe’s 2026 Push To Stay Relevant In Clinical Research

As Europe races to reclaim its share of commercial clinical trial activity, regulators are testing whether faster approvals and shorter setup timelines will be enough to restore sponsor confidence, attract biotech investment, and secure the region’s place in global drug development.

Infographic: Lessons From EU RADIAL On Scaling Decentralized Trials

The EU public‑private Trials@Home consortium put seven decentralized clinical trial elements to the test through its proof‑of‑concept RADIAL study to generate learnings on how to scale such trials in the future.

Patient Voice In New Zealand Trials Encouraged But Not Mandatory, Medsafe Says

Medsafe’s latest update of New Zealand’s clinical trial guidelines aligns with international standards and clarifies expectations on patient‑centric design, streamlined safety reporting, and other regulatory requirements.